JBIO Jade Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1798749 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY44.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-51.4%
ROA-47.4%
ROIC (approx.)-55.4%
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio16.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $30.82M | $50.06M | $36.05M | $28.54M | $22.01M | $22.55M | $20.02M | $17.57M |
| SG&A expense | $8.82M | $8.85M | $7.39M | $6.44M | $5.39M | $5.23M | $3.36M | $2.41M |
| Operating income | -$39.64M | -$58.92M | -$43.45M | -$34.98M | -$27.40M | -$27.78M | -$23.38M | -$19.98M |
| Pretax income | -$35.05M | -$55.75M | -$40.35M | -$31.87M | -$25.18M | -$32.13M | -$38.17M | — |
| Income tax | $10,000 | $15,000 | $16,000 | $58,000 | $0 | $0 | — | $0 |
| Net income | -$35.05M | -$55.77M | -$40.37M | -$31.93M | -$25.18M | -$32.13M | -$38.17M | -$30.11M |
| EBITDA | -$39.62M | -$58.91M | -$43.44M | -$34.97M | -$27.39M | -$27.78M | -$23.38M | -$19.98M |
| EPS (basic) | -0.42 | -0.76 | -0.57 | — | -0.48 | -0.86 | -12.10 | — |
| EPS (diluted) | -0.42 | -0.76 | -0.57 | — | -0.48 | -0.86 | -12.10 | — |
| Weighted avg. shares (diluted) | 71.76M | 61.05M | 57.78M | — | 39.58M | 28.43M | 3.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $80.39M | $107.25M | $55.09M | $88.44M | $50.11M | $220.94M | $44.22M | $69.39M |
| Short-term investments | $395.32M | $353.95M | $256.21M | $247.72M | $148.80M | — | $31.99M | $0 |
| Current assets | $485.56M | $471.25M | $318.52M | $348.82M | $201.36M | $222.98M | $77.37M | $69.65M |
| PP&E, net | $136,000 | $144,000 | $157,000 | $170,000 | $176,000 | $147,000 | $2,000 | $0 |
| Total assets | $486.39M | $472.11M | $319.43M | $349.78M | $202.45M | $223.97M | $77.53M | $72.80M |
| Current liabilities | $30.29M | $31.57M | $22.29M | $16.54M | $22.36M | $21.62M | $2.42M | $12.00M |
| Total liabilities | $30.89M | $32.20M | $22.97M | $17.26M | $23.10M | $22.41M | $2.49M | $119.60M |
| Shareholders' equity | $455.50M | $439.92M | $296.46M | $332.52M | $179.35M | $201.56M | -$83.51M | -$46.80M |
| Shares outstanding | 67.08M | 63.56M | 49.35M | 49.32M | 32.63M | 32.63M | 28.99M | 3.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.91M | -$43.66M | -$24.08M | -$33.65M | -$22.12M | -$36.53M | -$18.76M | -$15.81M |
| Capital expenditure | — | — | — | $3,000 | $57,000 | — | — | — |
| Free cash flow | — | — | — | -$33.65M | -$22.18M | — | — | — |
| Investing cash flow | -$42.30M | -$97.63M | -$8.47M | -$98.16M | -$148.71M | -$12.99M | $12.85M | $13.13M |
| Financing cash flow | $44.35M | $193.52M | -$795,000 | $170.16M | $0 | $191.31M | -$700,000 | -$2.77M |
| Depreciation & amortization | $16,000 | $9,000 | $9,000 | $9,000 | $12,000 | $1,000 | $4,000 | $8,000 |
| Stock-based compensation | $7.07M | $13.61M | $7.41M | $9.40M | $4.29M | $3.90M | $2.42M | $1.23M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.